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Abstract
The potential of the Ignatian Pedagogical Paradigm (IPP) is realized in the reflective actions of students after
they leave the Jesuit educational setting and go out into the world. With developments in science and
technology accelerating, and worldwide dissemination immediate, the imperative to infuse the IPP into areas
driven by science and technology is clear. It is this imperative which draws us to the global biotechnology
industry. This paper presents a short overview of the industry, describes how “science-business” differs from
traditional business, and discusses the process by which the IPP – context, experience, reflection, action and
evaluation – has been developed in the Business of Biotechnology program at the University of San Francisco
(USF). The cases developed to exemplify the IPP are “Organized Religion and the Business of
Biotechnology,” “Humanist Measures for Success in Bio-Business,” and “The Poor and Marginalized.” In
addition, the Business of Biotechnology program utilizes the Biotechnology Innovation Expertise Model
(BIEM 2.0), which identifies a recognized complement of the disciplines needed to bring breakthrough
bioscience to a commercial product. These disciplines are readily present at Jesuit universities, which can, in
turn, directly support education of value to the global biotechnology industry.
Introduction
There are times in human history when science
and technology make an unprecedented impact on
humans and the world in which they live, and, in
fact, set humanity on a course previously
unimagined. Obvious examples include the
printing press, telecommunications and
computers, and modern medicine. The
significance of a scientific breakthrough or a new
technology is typically not understood at its

outset, and the actual global adoption of a
technology often took decades. Today, however,
scientific breakthroughs and new technologies are
emerging at an unprecedented rate, information
can be shared globally within seconds, and
worldwide technology adoption can be
implemented within months.
In 2003, the genetic decoding of a severe acute
respiratory syndrome (SARS) virus from a single
patient took six days of round-the-clock work by a
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Canadian team, while a Centers for Disease
Control (CDC) team, working in parallel in
Atlanta, added further essential genetic details two
days later.1 SARS was determined to be different
from any previously decoded viruses found in
humans or animals by yet another team at
University of California San Francisco (UCSF) in
San Francisco. This feat was accomplished within
a single weekend.2 The genetic decoding of SARS
was a global scientific effort, led by the World
Health Organization (WHO) and involving “115
national health services, academic institutions,
technical institutions, and individuals.”3 It was
only possible through what is now considered
everyday communications technologies – voice,
conference calling, the Internet, computers, and
information sharing, all alongside the will and
intent of the scientists, scientific expertise, and
available equipment.
This moment of global crisis reveals the fabric of
the world in which our students will live, work
and contribute. It is a world in which individuals,
both independently and as participants in larger
organizations, can expect to be global actors. As a
result, infusing the Ignatian Pedagogical Paradigm
(IPP) into educational programs in fields driven by
science and technology carries great urgency. And
this imperative draws us to the global
biotechnology industry.
This paper presents a short overview of the
biotechnology industry and describes how
“science-business” differs from traditional
business through the lens of higher education.
This approach highlights how traditional
implementations of the IPP within business
education is insufficient, and discusses the
process by which the IPP – context, experience,
reflection, action and evaluation – has been
developed within the Business of Biotechnology
program in the School of Management at the
University of San Francisco (USF). The cases
developed below demonstrate the IPP as applied
to the global biotechnology industry. Our
examples include “Organized Religion and the
Business of Biotechnology,” “Humanist Measures
for Success in Bio-Business,” and “The Poor and
Marginalized.” Of note, the IPP is intentionally
distinguished from the topic of bioethics, which is
intrinsic to all biotechnology. Also discussed
below is how the Biotechnology Innovation

Expertise Model (BIEM 2.0) is used to
demonstrate that disciplines readily present at
Jesuit universities can directly support education
of value to the global biotechnology industry.
The Global Biotechnology Industry
Perhaps the most important aspect when
considering the global biotechnology industry is
its dual nature. While its goals are to feed all
people, heal all disease, and advance ecological
practices, at its core it is a collection of for-profit
businesses. As such, it must create a return on
investment to sustain itself, while much of the
world is incapable of participating in this
economic proposition.
We are now at an historic nexus of science and
technology. Genes of every living organism can be
decoded, analyzed, manipulated, inserted and
extracted. Out of this capability has grown the
global biotechnology industry, whose imprint on
humanity has only begun to be felt. In human
terms, biopharmaceuticals are at the heart of
precision medicine, offering exact diagnostics and
treatments based on a patient’s own DNA. On the
agricultural front, genetically-engineered droughtand pest-resistant crops are grown in 27 nations,
19 of which are designated as developing
countries. While some crops are transformed into
alternative fuel, others are foodstuffs and source
materials (e.g., cotton). In the manufacturing
sector, bio-engineered industrial enzymes continue
to replace polluting manufacturing processes,
supporting the sustainability of the planet.
In economic terms, the bio-pharmaceutical sector
sustained 2012 revenues in the $90 billion range,
while bio-fuels comprised $148 billion of the $5
trillion global fuel market. The reach of the
agricultural sector (AgBio) can be viewed as the
combined output of 420 million acres of
genetically-engineered crops planted worldwide.
And the economic sector of industrial enzymes
reports $3.5 billion in revenues in 2011.4
The global biotechnology industry creates many
opportunities in which individuals can bring about
reflective insight and responsible, creative action,
which in turn can broaden the industry’s reach to
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include all humanity. This is the promise of the
Ignatian Pedagogical Paradigm.
Is Bio-Business Different?
From an educational standpoint, it is important to
ask: Is there a compelling need to address the IPP
and the global biotechnology industry, separate
and apart from general business? Significant
efforts have long infused the IPP into Jesuit
business education. Is bio-business so different
from any other business? The response is
straightforward. First of all, the industry is based
on the continuous introduction of cutting-edge
science, with a focus on transforming scientific
breakthroughs into viable commercial
technologies. This is called “science-business,”
and the risks, the potential impact on lives, the
immediate applicability to all humans and all living
organisms, and the potential downsides are welldocumented.5
Unlike other businesses, the science-to-product
lifecycle also requires an extraordinary
complement of diverse expertise, and successful

interaction among the people involved. One
depiction of the expertise needed is the BIEM 2.0.
Its initial version was published in the Journal of
Commercial Biotechnology,6 where it identifies twelve
essential expertise categories needed by
bioenterprise, only one of which is science. BIEM
2.0 enabled the inclusion of bio-medical devices
along with bio-pharmaceuticals, agricultural
biotechnology and industrial biotechnology, by
adding science/technology in addition to simply
science. BIEM 2.0 is depicted in Figure 1.
While describing science-oriented business, many
of the disciplines found in BIEM 2.0 are regularly
taught at Jesuit institutions of higher learning in
non-science disciplines: intellectual property,
venture capital, finance, law, marketing, media,
ethics and bioethics, information systems, social
policy and multi-national expertise. They reach
across the university, while independently playing
a crucial and dynamic role in the innovative
science-to-product lifecycle. With the introduction
of ever-newer science and constantly-changing
technology, the need for individuals in every
discipline to incorporate Ignatian values is
paramount.

Figure 1: Bioenterprise Innovation Expertise Model (BIEM 2.0)
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Embedding the IPP in the Biotechnology
Science-to-Product Life Cycle

Case #1: Organized Religion and the
Business of Biotechnology

The Business of Biotechnology program at the
University of San Francisco was designed to
integrate the BIEM 2.0 disciplines of the
biotechnology science-to-product lifecycle, and to
engender students across these disciplines to study
together, as they will work together in industry. It
is comprised of four lecture courses and a
complement of one-week global study tours:

The orientation of the world’s major religions
toward biotechnology is set against a multinational geographic landscape, wherein products
must meet each nation’s regulatory environment,
while both understanding and respecting the
religious profile of its society. The religions
studied in the program include Roman
Catholicism and other Christian religions, Judaism,
Islam, Hinduism, and Buddhism, and any religion
or spiritual practice represented by students in the
class.

 MBA 6561 Local, National and Global BioBusiness
 MBA 6562 The Information of Biotech
 MBA 6563 Legal, Social & Ethical Implications
of Biotech
 MBA 6564 Bioentrepreneurship and the San
Francisco Bio-cluster (to be scheduled)
 MBA 6797 Biotechnology Global study tours:
including London/Oxford/Cambridge,
Switzerland, Montreal/Quebec City,
Washington, DC, and Sydney, Australia.
These courses draw students from degree
programs across the university, including: MBA,
JD/MBA, MS/Information Systems, Masters of
Public Administration, MS/Healthcare
Informatics, and Professional Science
Masters/Biotechnology, among others. The multidiscipline nature of bio-business provides a rich
opportunity for asking questions of the individual
in relation to the biotechnology industry in a
relevant, multi-disciplined setting.
The Strategy of IPP in Business of
Biotechnology Courses
Whether designed for individuals or groups, the
activities and exercises throughout all the courses
directly embrace Ignatian goals by incorporating
the five elements that make up the IPP: context,
experience, reflection, action, and evaluation. In group
exercises, the Context element requires that group
members reveal to each other (on a voluntary
basis) their individual context and framing
experiences, and similarly, all subsequent phases
require that dissimilar viewpoints are embraced
and respected. Three cases are offered as
exemplars of the IPP.

Eliciting comparative religious perspectives with
respect to biotechnology can be challenging. No
single viewpoint on the whole of biotechnology is
offered by any religion; rather, religious positions
typically relate to selective, specific
biotechnologies and identify positions on
particular circumstances of their use. Many
religions offer multiple interpretations, depending
upon their internal interpretive structures. Roman
Catholicism, for example, provides public
documents. The most recent positions of Roman
Catholicism vis-à-vis the use of biotechnology can
be found in the 2008 Vatican Instruction Dignitas
Personae on certain Bioethical Questions7 and a
complement of study reports from the Pontifical
Academy of Sciences regarding agricultural
biotechnology.8 These documents describe
relevant underlying science and technology using a
multi-layered framework for the Church’s or the
Academy’s position and its rationale.
By way of example, Dignitas Personae states: “The
dignity of a person must be recognized in every
human being from conception to natural death …
The Church moreover holds that it is ethically
unacceptable to dissociate procreation from the
integrally personal context of the conjugal act.”9
This confirms the Church’s longstanding rejection
of in vitro fertilization (IVF),10 which is not itself a
genetic biotechnical procedure. Still, the Dignitas
Personae Instruction recognizes that today a typical
precursor to IVF is pre-implantation genetic
diagnosis. This genetic test analyzes fertilized
embryos created via IVF external to the human
body and provides information regarding the
biological status of each prior to implantation in
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the prospective mother. Here the Church further
objects, and the many considerations presented
include the potential for the “qualitative selection
and consequent destruction of embryos” and
“treating the human embryo as mere ‘laboratory
material’.”11 Of note, Dignitas Personae is the first
instruction regarding biotechnology since the 1988
Vatican Instruction Donum Vitae,12 a time span
representing virtually the entire lifetime of the
commercial biotechnology industry. At the same
time, Dignitas Personae is a forward-looking
document, anticipating a number of projected
biotechnology developments.
While students are required to read the primary
source material of Dignitas Personae, multi-religion
insights are more often found in the peerreviewed literature and select textbooks.
Continuing on the theme of IVF and preimplantation genetic diagnosis, both individual
and multi-religion insights are available. Ari
Zivotofsky and Alan Jotokowitz published “A
Jewish Response to the Vatican’s New Bioethical
Guidelines,”13 and in “Assisted Reproductive
Technologies and World Religions: Implications
for Couples Therapy,”14 Jennifer Connor, et al.
discuss points of agreement and disagreement
across Judaism, Christianity, and Islam, providing
independent analyses of Judaism, Roman
Catholicism, Protestant Christianity, and Islam, as
well. The later paper is oriented to advising
couples and considers the implications of
generational familial beliefs, cultural perceptions
and legal impacts in some geographic areas. In
support of projects during the course, students
seek out sources in the literature relevant to their
focus area.
In a very few topic areas are textbooks available
and sufficiently up to date given the emergence
and adoption of biotechnology. One current
example in the agricultural biotechnology space is
Acceptable Genes? Religious Traditions and Genetically
Modified Foods,15 published in 2009 and edited by
Conrad Brunk and Harold Coward. It provides
insights from a series of authors regarding
Judaism, Christianity, Islam, Buddhism, Hinduism
and indigenous peoples. This is used in contrast to
the Pontifical Academy reports, 16 which are
supportive of genetically-modified agriculture in
the interests of feeding humanity. This book

focuses instead on religions wherein dietary laws
play a strict role.
The challenge is quite simply that biotechnology –
as with all technologies – continues to evolve,
while organized religions must respond with due
diligence and consideration. In fact, prior
positions may be re-evaluated and refined, new
positions must anticipate the response to future
technologies. Case in point, early stem cell
therapies derived source materials from embryonic
stem cells, which could not be approved by the
Roman Catholic Church. Yet, in Dignitas Personae,
stem cell therapies were projected to be acceptable
if adult stem cells could be used. While sourcing
from adult stem cells has not materialized
substantively as yet in the industry, there is
significant commercial research and development
underway, and arguably, stating the potential for
acceptability can affect the course of human
innovation. Other considerations in Dignitas
Personae include assessing risk to individuals with
each new technology and examining the potential
for passing genetic modifications on to progeny.
In-class discussions range from identifying the
religious profiles of various countries, to the
national acceptance/rejection of geneticallyengineered crops/food, to considerations about
the individuals with respect to religious and
spiritual practice, to students’ own experience,
actions and reactions.
One specific example used is Living Cell
Technologies, a New Zealand/Australian firm
which is working on placing insulin-producing
cells from pigs inside a nano-material sack
embedded beneath the skin. While these sacks
have successfully been shown in trials to be
effective in producing insulin for sustained
periods, it is important to consider that for those
of the Muslim and Jewish faiths, consumption of
pork is forbidden. Would this technology be
considered consumption? Would it be acceptable
if certain constraints could be met? How might
one address this? Other discussion points with
religious implications include: in vitro fertilization,
pre-implantation embryonic testing, embryonic
stem cell research, therapeutic cloning and animal
cloning.
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Individual assignments require that student select
a topic or product relevant to the biotechnology
industry. This could reflect a company, a
regulatory body, a nation, a law, an advocacy
group, etc. Students must then investigate their
choice with respect to a candidate organized
religion.
As an individual exercise, the following aspects are
included:
 Context: The individual’s own history vis-à-vis
organized religion, his/her current religious
orientation/affiliation (if any), and history visà-vis the candidate religion.
 Experience: The student is encouraged to relate
his/her own religious life experience to the
issue at hand. The student then performs a
differential analysis, if the candidate religion is
different from his/her own religion of origin.
 Reflection: As a part of the experiential process,
the student is asked to reveal elements which
are bothersome, disingenuous, problematic,
incomprehensible, frustrating, etc. regarding
the issue. Students are encouraged to interact
with those of relevant faiths – both inside and
outside of their class, if a religion other than
their religion of origin or personal choice was
selected.
 Action: Students are asked to propose potential
actions and solutions. Frequently, these relate
to the discipline of their degree program; thus,
students are encouraged to interact with those
from other disciplines to expand perspectives,
enlarge options, review viability, etc.
 Evaluation: Students are asked to share their
experience of understanding the issue and their
attempt to create workable solutions. This
includes understanding the basis for false
starts, what could and could not be resolved
with the actions proposed, and what remains to
be addressed.
As a group exercise, adjustments are made to take
advantage of a mixed-discipline, potentially mixedreligion group with the capability of creating far
more diverse solutions. They quickly dispatch
unworkable solutions, given insights from
particular disciplines. Group exercises give the
students experience in respecting all involved.

Case #2: Humanist Measures for Success in
Bio-Business
Traditional business measures fall short when
applied to bio-business, especially when the
successful use of biotechnology products can save
human lives and/or reduce human suffering.
One example presented to Business of
Biotechnology students is Genomic Health, Inc., a
profitable, publicly-traded genetics diagnostics
firm (GHDX [NASDAQ]) which specializes in
improved diagnostics for breast, colon and
prostate cancers. In the case of breast cancer
patients where chemotherapy is the recommended
standard of care, only four in 100 women who
receive chemotherapy actually benefit from the
treatment. Most patients and their doctors choose
the chemotherapeutic option in the hope that they
will be one of the four per cent for whom it will
work.
Since its introduction, Genomic Health’s
Oncotype DX test has provided further analysis
of tumors’ genetic composition. Is the cancer
aggressive? Will it be responsive to chemotherapy,
and to which particular chemotherapy drugs?
In a 2012 Canadian decision-impact study,
physicians changed their treatment
recommendations 30% of the time given the
result of the Oncotype DX test. Within those
decision changes, 20% of the patients were
advised to omit chemotherapy, while 10% were
advised to add particular chemotherapy when test
results predicted the treatment would be
beneficial. Since the test became available, the use
of chemotherapy in the United States for these
specific conditions has steadily declined, which
turn reduces the suffering caused by uninformed
treatments.17
At the same time, Genomic Health has come
under pressure from financial industry analysts to
reduce the 20% it feeds back into its budget for
further research and development (R&D). A more
typical R&D re-investment range might be 5%9%. Measuring “suffering saved” enables
economics to be balanced with service to others,
while the company remains financially sound.
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Class discussion revolves around attempting to
identify other conditions for success, such as
alleviating human suffering, reducing impact on
families, arguing for long-term goals vs. shortterm return, quantifying value in non-economic
terms, etc.
Individual assignments require that students select
a non-economic, atypical measure for success,
then select a candidate company/product to
evaluate. These individual exercises include the
following aspects:
 Context: The individual’s own history with
respect to this measure and the candidate
company/product.
 Experience: Students are encouraged to relate in
their own words why that measure is important
and its impact on people and society external
to his experience.
 Reflection: As a part of the experiential process,
students are asked to describe the impact on
individuals and society if this measure was
achieved.
 Action: Students are asked to propose potential
actions and solutions. These solutions may
include changes to basic business models, laws,
social policy, regulations, etc.
 Evaluation: Students are asked to express their
experience with this exercise and how they
personally felt with the realization that this
could be an actual measure of success.
As a group exercise, the experience matches that
of Case #1.
Case #3: The Poor and Marginalized
In 2001/2002, Gilead Sciences, Inc. (GILD
[NASDAQ]) received approval for its HIV
medication Viread in the United States and
Europe. Taken once per day orally with a meal,
Viread was a breakthrough for patients, as
previous medications required multiple pills at
varying intervals. With patent protection through
2017/2018, this period is typically used in the
pharmaceutical industry to recover investment and
establish full profitability. But in 2003, Gilead put
into place an access program enabling all African
countries and 15 other nations identified by the
United Nations as “least-developed” to obtain

Viread at non-profit cost. Of note, it was
implemented well in advance of recovering the
investment made to develop and bring Viread to
market, and it was presented as a separate
calculation from that endeavor. Two years later,
Gilead further reduced the cost of Viread by 37%,
to approximately $0.82/day at a time when the
full retail price of the drug was approaching
$20.00/day.18
Today, 4.7 million people in low- and middleincome countries receive Gilead HIV therapies at
reduced pricing through a variety of innovative
economic programs, including voluntary generic
licensing and local business partnering.19
Students are asked to consider the premise: If a
technology exists that relieves a disease, is it
inhumane to deny it to any human?
Individual assignments require that students think
inventively about addressing the totality of human
needs, while creating and nurturing economicallyviable business propositions. They are asked to
design programs which serve all humanity from
the outset, and they are encouraged to invent new
business groundrules. As an individual exercise,
the following aspects are included:
 Context: The student is asked to pick a product
– approved or not yet approved, real or
fictitious. The individual is asked to reveal
his/her own history with respect to the
treatment and/or condition.
 Experience: The student is encouraged to
explore all the people globally who require the
treatment, and their actual condition: socioeconomic, environmental, etc. The student is
asked to reveal what groups or situations s/he
found surprising in this quest.
 Reflection: As a part of the experiential process,
the student is asked to reveal which people
affected him/her the most, and what s/he
learned that s/he did not know, and needed to
know, or s/he would not have a workable
action.
 Action: Students are asked to propose potential
actions and solutions. These solutions may
include changes to basic business models, laws,
social policy, regulations, etc. There may be
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multiple solutions, or only solutions for some
subgroups.
 Evaluation: Students are asked to express their
experience with this exercise, and to evaluate
what solutions were successful and what
problems remain to be addressed.
As a group exercise, the experience matches that
of Cases #1 and #2.
Bioethics, the IPP, and Curriculum Values
It should be stated that bioethics is a separate and
important field, with a larger purview than today’s
biotechnology industry. Furthermore, ethical
challenges are typically not the driver of new
action. Through the IPP, an individual can have
the vision to improve on an ethical situation,
producing a greater human benefit. Aspects of
bioethics relevant to the biotechnology industry
are included throughout the Business of
Biotechnology curriculum on a specific basis, and
should not to be confused with the incorporation
of the IPP into assignments, the personal journey
IPP seeks to engender, or the habit of creative
action IPP supports. While bioethical issues can
sometimes overlap with IPP-embedded exercises,
they are not one and the same. Margaret McLean,
the Director of Biotechnology and Health Care
Ethics at the Markkula Center for Applied Ethics
at Santa Clara University refers to this area of
bioethics as “biotech ethics” and provides a more
biotechnology industry-relevant framework in
what she terms “Reasoning into Biotech
Practice.”20 It is essentially this “biotech ethics”
framework which is largely utilized throughout the
USF curriculum.
Another aspect which relates to this topic is the
question of values and IPP practice measurement
among adult students. Graduate student practices
of reflection over time within a degree program
were measured, presented and discussed by Coiro,
et al.,21 with focus on the reflection portion of the
IPP and the adult student. This is particularly
germane to students in the Business of
Biotechnology courses, as they are all postgraduate. Complementary research has begun and
is in its formative stages in the Business of
Biotechnology Program, measuring student
perception of Jesuit values as expressed in USF’s

mission and values statement and its reflection in
individual course content. In some cases, this has
been measured on exit, while in others, it is being
measured on a differential entry-and-exit basis.
This is an extension of the GLAS project, the
Gunn-Lorton Attitudinal Survey, which also
includes undergraduate testing. This approach of
“testing the course” is at its center of focus,22 and
it proves to be a complex, yet important, question.
U.S. Jesuit Universities and BioenterpriseRelevant Education
Taken together, the capability of the 28 U.S. Jesuit
universities to address bioenterprise-relevant
education is undeniable. They sustain three
medical schools, and six PhD programs in
Biology. Fourteen of these universities host law
schools, another fourteen offer joint JD/MBA
degrees, six offer a Masters in Biology, and all 28
U.S. Jesuit universities have Biology departments.
All but one of these universities have a business
school.
Specific bioenterprise-relevant education varies
with other degree programs in place. In the area of
the biopharmaceuticals, these courses may
embedded within healthcare management
programs. St. Joseph University offers a
Pharmaceutical and Healthcare Marketing MBA
for Executives, while both Gonzaga University
and Loyola University Chicago offer MBAs in
Healthcare Management. Marquette University
offers a Masters in Healthcare Technology
Management.
Health informatics is represented by such
programs as St. Joseph’s Online Masters in Health
Administration with an Informatics Specialization,
while Le Moyne College offers a certificate for
working professionals in Health Information
Systems. The University of San Francisco has
commenced a Masters in Health Informatics in
online, onsite and hybrid forms originating from
the School of Nursing and Health Professions.
Jesuit law schools are participating in the
biotechnology field with Santa Clara University’s
focus on biotechnology law. SCU offers such
courses as Assisted Reproduction, Cloning, and
Genetic Engineering, as well as a Biotechnology
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Law Seminar. SCU’s offering is complemented by
the Markkula Center for Applied Ethics’ focus on
bioethics. St. Louis University School of Law
offers the course Biotechnology Law and Policy,
while USF’s School of Law offers courses on
Science and the Law, and Biotechnology Law.
In addition to its Business of Biotechnology
program described earlier, USF commenced a
Professional Science Masters in Biotechnology
degree program in its College of Arts & Sciences
in 2012, collaborating with the Business of
Biotechnology program to achieve the required
topical business credits. Creighton University had
less success with its Professional Science Masters
(PSM) in Bioscience Management. This is due in
some part to the fact that Omaha is a challenging
geographic area in which to recruit the PSMrequired biotechnology internships from local biobusinesses. Still, Creighton has continued with its
undergraduate Bioscience Management track in
the Marketing and Management bachelors
program.
Since 2008, USF has offered a Masters in
Information Systems with a concentration in
Biotechnology, which incorporated Business of
Biotechnology courses. In engineering, Marquette
University has a full roster of degrees in the field
of Biomedical Engineering – ranging from
bachelors to PhD. Fordham University offers a
certificate in biomedical informatics.
This overview of Jesuit education in the field of
bioentrepreneurship is not meant to be
exhaustive, but rather to demonstrate that every
Jesuit university has the capability to support
many aspects of bio-business, as demonstrated by
the BIEM 2.0 model. Such programs can be
developed by a roster of interested faculty across
schools in the respective universities and can
incorporate efforts already underway to develop
flexible, cohesive, university-wide bioenterprisefocused programs. Each course and each program
can incorporate the IPP successfully in every
instance. Also, the success of engendering nonscience professional graduate students with
significantly increased comfort levels toward the
biotechnology industry was measured on
successive study tours to global bio-clusters.23 It is
indeed possible to develop an appreciation for and

understanding of the global biotechnology
industry for those with no formal science training
in their undergraduate and graduate university
experience.
It should be noted that a complement of nonJesuit higher education bioentrepreneurship
courses and programs have emerged globally in
recent years. Dr. Lynn Johnson Langer, a
program director at the Johns Hopkins
University’s Center for Biotechnology Education,
cites a selected list of 26 such bioentrepreneurship
programs in “Building a Curriculum for
Bioentrepreneurs”, which was published in Nature
Biotechnology Bioentrepreneur.24 Of the 26 programs
identified, 19 are located in the United States,
while only one is at a Jesuit university (USF).
Bioentrepreneurship programs are just now taking
shape for good reason – the U.S. biotechnology
industry has matured and its employment needs
are now on the rise. In this case, employment
potential is driving development of academic
programs.
Conclusion: The IPP and the Global
Imperative of Biotechnology
While biotechnology naturally attracts those who
wish to serve others, the industry is problematic as
a profitable business proposition. Biotechnology
products require astonishing investments over
many years, and efforts are continually fraught
with the looming specter of failure. At the end of
this period, there are only a relatively few years to
recover the investment and generate profits. The
2014 report from the Tufts Center for the Study
of Drug Development estimates the cost to
develop a successful new drug to be $2.6 Billion.25
Of the some 1,400 drug compounds the report
examined, only 7% were approved, 80% were
discontinued, and 13% were still actively being
pursued. If all the currently active drug candidates
succeed, it still means that 4 out of 5 fail. And
successful drugs can take 11-15 years to reach
approval.26
But the rewards of working in the biotechnology
industry refuse to be measured by such standards.
With success, biotechnology can save lives, reduce
suffering, change the world for the better, and
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lead us all to know ourselves in ways we never
previously imagined.
The importance of a Jesuit education is that it
goes beyond business fundamentals and
hypothetical discussions of the ethical issues
involved – it teaches the individual about the
importance of context. It is a call to reflect, a
requirement to experience, a freedom to create
innovative action, and a habit of evaluation. This
paper seeks to document both the importance of
instilling Ignatian values in the burgeoning
biotechnology sector, as well as the ability of Jesuit
universities to educate both scientific and nonscientific biotechnology industry professionals.
But the premise is greater than that. The role for
Jesuit education in supporting the biotechnology
industry is a higher calling: To educate those who
will participate in bioenterprise with an
appreciation for the world, a respect for life –
both individually and collectively, a sense of
relevancy to the moment, a penchant for realistic
assessment, an inclusionary vision of religion and
spirituality, a larger definition of values, a sense of
participating in a great human quest for good, an
increased sense of self in a changing world, a
sensibility to include the poor and marginalized in
unprecedented ways, a perception that new rules
can be made and new systems built, and a license
to act in a larger context.
This is a promise on which Jesuit education can
deliver.
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